Skip to main content

Limoneira Company(LMNR-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Ikena Oncology Presents Data at SITC 36th Annual Meeting Describing the Indication Selection Methodology, Translational Data, and Trial in Progress for IK-175

Globe Newswire - Fri Nov 12, 2021

Data supports and describes the ongoing Phase 1a/b clinical trial of IK-175 as a single agent and in combination with nivolumab in advanced solid tumors

Study evaluates IK-175 in urothelial carcinoma patients including AHR positive enriched subpopulation  

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe